KPV Peptide: Sequence, Research Evidence and Batch Testing

Chemical Identity

For general laboratory handling principles, see the Pureline Biolabs peptide reconstitution guide and reconstitution calculator.

The molecular weight above can be checked directly from the sequence. Lysine, proline and valine have residue masses of 146.19, 115.13 and 117.15 g/mol; condensing three amino acids into a tripeptide removes two water molecules, giving 378.47 minus 36.03, or 342.44 g/mol.[1] Salt forms, counterions, water content and protonation state can change the formula weight reported for a supplied preparation, so the material description on the analytical report should be compared rather than relying only on a general database entry.

What KPV Is, and What It Is Not

KPV takes its name directly from the one-letter abbreviations of its three amino acids: lysine, proline and valine. The same sequence appears at positions 11 to 13 of alpha-MSH, a longer peptide involved in melanocortin biology.

KPV therefore shares a structural relationship with alpha-MSH, but the two should not be treated as interchangeable. Removing most of the parent peptide changes its receptor interactions, transport behaviour and biological context. A finding involving full-length alpha-MSH is not a KPV finding.

KPV research has attracted attention partly because such a short sequence can still influence inflammatory responses in certain experimental models. Its length also makes it a useful subject for studies of peptide transport, particularly through PepT1, the transporter that carries dipeptides and tripeptides across cell membranes.

Why the Lys-Pro-Val Sequence Matters

Each residue contributes different chemical properties. Lysine carries a basic side chain that can hold a positive charge under common experimental conditions. Proline introduces a rigid ring that restricts movement along the peptide backbone. Valine contributes a hydrophobic side chain at the C-terminal end.

Together these form the C-terminal KPV sequence found within alpha-MSH. Identifying the sequence does not by itself establish a biological result. Activity depends on the test model, concentration, formulation, exposure conditions and analytical method used.

Evidence by Research Level

Not every KPV finding carries the same weight. Separating evidence by model type prevents cellular observations being presented as established human outcomes.

In-Vitro Research

A 2008 study examined KPV in human intestinal epithelial cell lines and Jurkat T cells. It reported that nanomolar KPV reduced activation of NF-kappaB and MAP kinase signalling and reduced secretion of pro-inflammatory cytokines under the conditions tested. Transport experiments in the same study linked cellular uptake to PepT1.[3]

That finding relates to those specific cultured-cell systems. It does not show how a separate preparation would behave in a person. Other laboratory work has investigated KPV and related alpha-MSH fragments in immune, epithelial and microbial models. Modified peptides such as CKPV derivatives or KPV dimers are different test articles and should not be treated as equivalent to unmodified Lys-Pro-Val.

Animal Research

KPV has been examined in several mouse inflammation models. In DSS-induced and TNBS-induced colitis models, KPV added to drinking water was associated with lower inflammatory-marker expression and changes in histological measurements. Separate work using a T-cell transfer model reported reduced inflammatory changes following KPV treatment.[4]

A crystal-induced peritonitis study reported reduced accumulation of polymorphonuclear leukocytes after KPV administration, and indicated that KPV did not act in the same way as the central melanocortin receptor-binding sequence of alpha-MSH.[2]

These were controlled animal experiments using induced disease models. They do not establish an effect, a safe exposure level or a suitable route in humans.

Human Research

No controlled human clinical trial establishing the safety or efficacy of isolated KPV was identified in the literature reviewed for this page.

This distinction is worth stating plainly, because it is easily blurred. References in the literature to human intestinal cells, human immune cells or human bronchial cells describe laboratory cultures of human-derived cells. They do not mean that KPV was administered to human participants.

What Is Not Established

Pureline Biolabs does not present KPV as a treatment for inflammatory bowel disease, skin conditions, digestive disorders or any other medical condition.

Current Pureline Batch

The values above are taken from the Janoshik report for the sample submitted from batch PLB-011. Two points of accuracy are worth stating. First, the certificate reports a measured amount and a purity percentage; it does not state the analytical method by name, and it does not report a separate identity, sterility, endotoxin or sequence-confirmation result. None of those should be inferred from it. Second, the sample name field on the certificate reads KVP, a transposition of KPV; the tests-requested field and the results row on the same certificate both read KPV, and Pureline has asked the laboratory to correct the sample label. The measured amount of 9.82mg is below the 10mg labelled vial size. This panel is updated when Pureline changes to a new batch, and earlier reports are kept under their original batch codes rather than replaced.

What the Test Results Show

The certificate for batch PLB-011 covers the first two rows of that table only. Mass spectrometry, endotoxin and sterility testing were not commissioned for this batch, and the page makes no claim about them.

A 98.015 per cent purity result answers one narrow analytical question. It does not mean the vial is 98 per cent correctly filled, 98 per cent sterile or 98 per cent safe.

KPV Compared With Related Research Peptides

Common Questions